Ozanimod (Zeposia)
Ozanimod (Zeposia) is an oral treatment approved for relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease (RRMS), and active secondary progressive disease, in adults. Ozanimod is a sphingosine-1-phosphate receptor modulator similar to other MS therapies including fingolimod and siponimod that trap some white blood cells (lymphocytes) in lymph nodes, thus preventing their availability to cause damage to the central nervous system. Ozanimod does not require genotyping before initiation and does not require first dose observation.
Additional Information
- National MS Society Zeposia
- VA Ozanimod (Zeposia) Drug Monograph (VA access only)
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
